Screening for lung cancer: what have we learned?
- PMID: 24555588
- DOI: 10.2214/AJR.13.11540
Screening for lung cancer: what have we learned?
Abstract
Objective: The purposes of this article are to briefly review the history of lung cancer screening, discuss the results and implications of the National Lung Screening Trial, and address some of the questions that remain since the publication of this landmark study.
Conclusion: Lung cancer remains the leading cause of cancer-related death in the United States and the world. The National Lung Screening Trial showed a 20% reduction in lung cancer mortality among individuals at high risk undergoing low-dose CT. The findings opened the door for clinical lung cancer screening and publication of lung cancer screening guidelines. However, many questions remain, including whom to screen, how often, and for how long. Furthermore, costs and effects on the health care system remain unclear.
Similar articles
-
Lung Cancer Screening With Low-Dose CT in the United States.J Am Coll Radiol. 2015 Dec;12(12 Pt B):1395-402. doi: 10.1016/j.jacr.2015.09.016. J Am Coll Radiol. 2015. PMID: 26614885
-
Underuse of Chest Radiography Versus Computed Tomography for Lung Cancer Screening.Am J Public Health. 2017 Aug;107(8):1248-1250. doi: 10.2105/AJPH.2017.303919. Am J Public Health. 2017. PMID: 28700293 Free PMC article. No abstract available.
-
Results of the national lung cancer screening trial: where are we now?Thorac Surg Clin. 2015 May;25(2):145-53. doi: 10.1016/j.thorsurg.2014.11.002. Epub 2015 Feb 2. Thorac Surg Clin. 2015. PMID: 25901558 Free PMC article. Clinical Trial.
-
Contributions of the European trials (European randomized screening group) in computed tomography lung cancer screening.J Thorac Imaging. 2015 Mar;30(2):101-7. doi: 10.1097/RTI.0000000000000135. J Thorac Imaging. 2015. PMID: 25635703 Review.
-
Lung cancer screening: the radiologist's perspective.Semin Respir Crit Care Med. 2014 Feb;35(1):91-8. doi: 10.1055/s-0033-1363455. Epub 2014 Jan 30. Semin Respir Crit Care Med. 2014. PMID: 24481763 Review.
Cited by
-
PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.Oncogene. 2019 Nov;38(48):7311-7328. doi: 10.1038/s41388-019-0950-z. Epub 2019 Aug 16. Oncogene. 2019. PMID: 31420605 Free PMC article.
-
MiR-98 inhibits cell proliferation and invasion of non-small cell carcinoma lung cancer by targeting PAK1.Int J Clin Exp Med. 2015 Nov 15;8(11):20135-45. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26884926 Free PMC article.
-
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening.J Vis Exp. 2017 Oct 26;(128):56326. doi: 10.3791/56326. J Vis Exp. 2017. PMID: 29155727 Free PMC article.
-
Protein kinase Cα mediates erlotinib resistance in lung cancer cells.Mol Pharmacol. 2015 May;87(5):832-41. doi: 10.1124/mol.115.097725. Epub 2015 Feb 27. Mol Pharmacol. 2015. PMID: 25724832 Free PMC article.
-
Lamprey Immune Protein Mediates Apoptosis of Lung Cancer Cells Via the Endoplasmic Reticulum Stress Signaling Pathway.Front Oncol. 2021 Jul 7;11:663600. doi: 10.3389/fonc.2021.663600. eCollection 2021. Front Oncol. 2021. PMID: 34307136 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical